Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

23.05.2018 | short review

ASH 2017: highlights in chronic myeloid leukemia

verfasst von: Klaus Geissler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Summary

Despite remarkable achievements in the management of chronic myeloid leukemia (CML), there remain a number of challenges in the field. At the American Society of Hematology (ASH) Meeting 2017 several presentations addressed current problems around the topics CML stem cells, progression of CML into blast crisis (BC), and personalized treatment.
Vorheriger Artikel Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
Nächster Artikel Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting
Literatur
1.
Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11(1):56–71.CrossRefPubMed
2.
Bocchia M, Aprile L, Sirianni S, et al. Peripheral blood flow-cytometry chronic myeloid leukemia stem cells detection and Quantification during tyrosine kinase inhibitors therapy. Blood. 2016;128(issue22):abstr942.
3.
Bocchia M, Defina M, Sirianni S, et al. Persistence of residual circulating CD26+ leukemia stem cells in chronic myeloid leukemia patients in treatment free remission. Blood. 2017;130(suppl1):abstr249.
4.
Khorashad JS, Eiring AM, Mason CC, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 2015;125(11):1772–81.CrossRefPubMedPubMedCentral
5.
Than H, Pomicter AD, Mason CC, et al. Inhibition of nucleocytoplasmic export enhances selective elimination of leukemic stem cells in chronic myeloid leukemia. Blood. 2017;130(suppl1):abstr42.
6.
7.
Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood. 2017;130(suppl1):abstr247.
8.
Branford S, Wang P, Yeung D, et al. Integrative genomics reveals cancer associated mutations are common at diagnosis of CML in patients with poor response to TKI therapy. Blood. 2017;130(suppl1):abstr251.
9.
Awad AS, Kankainen M, Eldfors S, et al. Identification of progression-associated mutations in Chronic Myeloid Leukemia (CML) by comparative genomic analysis. Blood. 2017;130(suppl1):abstr250.
10.
Mancini M, De Santis S, Monaldi C, et al. SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia. Blood. 2017;130(suppl1):abstr43.
11.
Magistroni V, Piazza R, Mauri M, et al. De novo UBE2A mutations are recurrently acquired during CML progression and interfere with myeloid differentiation pathways. Blood. 2017;130(suppl1):abstr44.
12.
Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777–83.CrossRefPubMedPubMedCentral
13.
Hehlmann R, Lauseker M, Saussele S, et al. Final evaluation of randomized CML-study IV: 10-year survival and evolution of terminal phase. Blood. 2017;130(suppl1):abstr897.
14.
Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed Chronic Myeloid Leukemia: 12-month patient-reported outcomes from the BFORE trial. Blood. 2017;130(suppl1):abstr2895.
15.
Turkina AG, Shukhov O, Chelysheva E, et al. PF-114 mesylate, a novel third generation ATP-competitive BCR-ABL tyrosine kinase inhibitor: first safety and efficacy data from a phase I study in patients with CML with failure of prior TKI therapy. Blood. 2017;130(suppl1):abstr895.
16.
Saussele S, Richter J, Guilhot J, et al. “Duration of Deep Molecular Response” Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia—Results from the EURO-SKI Trial. Blood. 2017;130(suppl1):abstr313.
Metadaten
Titel
ASH 2017: highlights in chronic myeloid leukemia
verfasst von
Klaus Geissler
Publikationsdatum
23.05.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0406-0

Weitere Artikel der Ausgabe 2/2018

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania

  • Open Access
  • original report

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

  • review

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

  • editorial

Educational no. 1: Bone marrow diagnostics in hemato-oncological diseases

  • educational

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting

  • short review

Laboratory diagnostics in hematology — a new “Educational” series

  • editorial